75 results about "Peptide expression" patented technology

The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.

The invention provides a method for making in vitro peptide expression libraries, and for the isolation of nucleotide sequences encoding peptides of interest, wherein the peptides or proteins are specifically associated with the DNA encoding them through non-covalent protein:DNA binding. The method describes ways of making the library itself, DNA molecules encoding the library and uses of the expression library.

The invention provides a method for making in vitro peptide expression libraries, and for the isolation of nucleotide sequences encoding peptides of interest, wherein the peptides or proteins are specifically associated with the DNA encoding them through non-covalent protein:DNA binding. The method describes ways of making the library itself, DNA molecules encoding the library and uses of the expression library.

The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides.

The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides.

The invention provides a method for producing a recombinant polypeptide of interest which method comprises: (a) providing a host cell which comprises a nucleotide sequence which encodes the recombinant polypeptide of interest and which directs expression of the recombinant polypeptide of interest in the host cell; (b) providing a serum-free culture medium which comprises (i) water, a plant-derived peptone, an osmolality regulator, a buffer, an energy source, at least one amino acid, a lipid source or precursor, a source of iron, non-ferrous metal ions and optionally one or more vitamins and cofactors; and (ii) does not contain any full-length polypeptides; and (c) culturing the host cell in the culture medium under conditions that allow for expression of the recombinant polypeptide of interest.

This invention is directed to methods for manipulating sex, reversing sex, changing sex ratio, or moderating crustacean androgenic gland peptide expression in crustaceans for producing a monosex culture. In one embodiment, the present method comprises the step of injecting a dsRNA for the gene of IAG into a male crustacean. In another embodiment, the present method comprises the step of injecting a dsRNA for the gene of IAG into a female crustacean that had acquired a spermatophore (a sperm sac) after mating with a male. In another embodiment, the present invention provides a method of producing a monosex culture of crustacean by introducing a recombinant IAG peptide into the female crustacean, thereby obtains male with altered sexual characteristics for mating with a normal female. In one embodiment, the crustacean is a shrimp or lobster.

The invention is directed to expression of non-plant proteins in rice plants. Expression is optimized by use of a non-rice promoter of a monocot protein gene and its corresponding signal peptide for expression of the non-plant protein in rice plant at high yields. The invention is useful for making human proteins, polypeptides and peptides in rice seeds. The expressed protein product can be isolated from the rice seed for administration to humans or other animals.

An improved method for recovering recombinantly produced polypeptides is described. The method involves expressing the recombinant polypeptide as a fusion protein with a pro-peptide. The pro-peptide-polypeptide fusion protein can be cleaved and the recombinant polypeptide released under the appropriate conditions.

The invention is directed to methods and metric suitable for use in modulating the expression of a polypeptide encoded by a nucleic acid sequence. In certain aspects, the invention also relates to methods for introducing modifications in a polypeptide, for example through substitution of one or more nucleic acids in an untranslated sequence or in a coding sequence of a nucleic acid sequence encoding a polypeptide to increase the expression of the polypeptide.

The invention provides a recombinant phage double expression vector and application, relating to the technical field of biology. The recombinant phage double expression vector is a recombinant double expression vector obtained after inserting a target gene 1 into the downstream part of a gene p10B in a T7 phage genome and inserting a eukaryotic expression cassette containing a target gene 2 into a non-coding region in the T7 phage genome. The recombinant phage double expression vector has high stability, can display the protein coded by the target gene 1 on the surface of the phage, simultaneously can transfer the eukaryotic expression cassette into an immune cell to achieve eukaryotic expression of the target gene 2, and can serve as a common platform for expression of various epitopes, namely polypeptides. Immune efficacy detection finds that bodies can generate high-level VP1 structural protein antibodies against foot and mouth disease viruses after being immunized by the vaccine, and the antibodies have long duration.

An aptamer-mRNA conjugate is provided. The aptamer-mRNA conjugate may include an aptamer component that binds a membrane associated protein on a target cell and an mRNA component that is expressed by the target cell.

Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.

The invention discloses a method for detecting serum polypeptide for kidney transplantation rejection. The method comprises the following steps of: 1, classifying the previously collected serum samples according to the seriousness of the disease of a donor; 2, capturing the polypeptide from the serum in the serum sample groups by using MB-WCX respectively and concentrating the polypeptide on magnetic balls to form tie molecules; 3, eluting the tie molecules from the magnetic balls and performing MALDI-TOF mass spectrometric analysis; classifying the different peptide peaks measured from the samples of each group to establish a classifying and predicting model so as to acquire a difference peptide expression map; 4, combining the serum samples of a kidney transplantation rejection patient to be detected by using the MB-WCX, then performing the MALDI-TOF mass spectrometric analysis and comparing the analysis result with the map acquired in the step 3 so as to mark the peptide of the serum sample. The method contributes to understanding the pathogenesis for the kidney transplantation rejection well from the level of the proteomics and makes the early diagnosis of the kidney transplantation rejection possible.

Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.

The present invention relates to a system and methods for identifying differential peptide expression in one or more peptide populations. Each population is labeled with a discernable label and provides a mechanism to resolve mixed peptide populations using mass spectroscopy-based techniques. Spectra produced by the peptide sample are used to interrogate a spectral database in which peptide sequences of known spectra are stored. In addition to providing sequence information, the methods presented herein may be used to determine qualitative and quantitative measurements of peptide expression. These measurements may further be used to determine proteomic differences and novel peptide expression.

The invention provides expression vectors that support high levels of polypeptide expression in mammalian cells. The vectors contain at least one expression cassette for a target polypeptide; an expression cassette for a eukaryotic selectable marker protein; an expression cassette for a bacterial selectable marker protein, and a bacterial plasmid origin of replication.

New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, and new organisms, a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related and discloses selected endotoxins we call cysteine rich insecticidal peptides (CRIPS) which are peptides derived from Bacillus thuringiensis (Bt) and their genes and endotoxins in combination with toxic peptides known as Inhibitor Cystine Knot (ICK) genes and peptides as well as with other types of insecticidal peptides such as trypsin modulating oostatic factor (TMOF) peptide sequences used in various formulations and combinations; of both genes and peptides, useful for the control of insects.

The invention discloses a method for producing a simeglutide precursor by high-density fermentation of recombinant escherichia coli. In order to solve the problem that the expression quantity of semeglutide produced through fermentation at present is low, the Mg ion concentration is remarkably increased in a high-density fermentation culture medium of prepared recombinant escherichia coli for expressing a semeglutide precursor, the induction OD value of fermentation culture is increased to 150 or above, the fermentation OD value of the recombinant escherichia coli and the thallus biomass of inclusion bodies are remarkably increased, the high-density fermentation effect of the recombinant engineering bacteria is realized, and the expression quantity of a semeglutide precursor is obviously increased.

Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein / peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets.

The present invention is multicopy beefy meaty peptide (BMP) and its expression gene, vector and construction process in recombinant Pichia pastoris, and relates to molecular biotechnology. Based on the codon partiality expressed and translated with Pichia pastoris, are designed a 4 copy BMP expressing gene sequence and essential limiting cleavage sites, 6His and a termination codon. Through in vitro operation, the copy number is increased to 16, the BMP is inserted to expression vector pPIC9, and after linearization of pPIC9, the 16 copy BMP expressing gene as the target segment is recombined onto the Pichia pastoris genome by means of electric transformation. BMP is obtained in high yield through fermentation and methanol induction of Pichia pastoris, and is separated and purified in 6His affiliated Ni column.

The present invention relates to the expression and purification of recombinant protein in the field of gene engineering, and is especially the high efficiency production process of recombinant silkworm antibiotic peptide. Technologically, the high efficiency production process of recombinant silkworm antibiotic peptide includes the following steps: 1) constituting ABP-CM4 eukaryotic expression vector by means of DNA technology; 2) transforming host cell Pichia yeast with ABP-CM4 eukaryotic expression vector to constitute expression engineering bacteria; 3) fermentation culturing the engineering bacteria and performing methanol inducing expression; and 4) purifying expression product through chromatography with molecular sieve column to obtain recombinant silkworm antibiotic peptide CM4 product. The present invention has high expression efficiency, simple separation and purification and other advantages, and is suitable for industrial production.

Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and / or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite. This system offsets some side effects caused by free anabolic drug, such as high blood calcium concentration

Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with a special selection of hosts, and / or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special universal cloning vectors are provided for the preparation of expression vectors which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.

The invention relates to a method for preparing recombinative reducing peptide, which uses DNA recombinant technology and prepares by gene engineering bacteria invoice method, and especially to the related gene design and synthesis of recombinative reducing peptide, construction of recombinative reducing peptide expression carrier, host conversion with the said expression carrier and construction of the gene engineering bacteria, and fermentation production of recombinative reducing peptide by the said gene engineering bacteria. First an anterior peptide should be designed, in which the peptide can be materials with repetition of one reducing peptide or mixed materials of several reducing peptides. For example, this invention adopts mixed peptides including LRP, LYPVK, AVNPIR, GHKIATFQER and AVPYPQR. Then the representation system pET-28a (+) of bacillus coli BL21 (DE3) is adopted and the amino acid sequence of the anterior peptide is transformed into single stage DNA sequence. Subsequently, the code genes of fused protein comprising this five reducing peptides are designed, the genes are synthesized with chemical method and are connected on the expression carrier, and the suitable positive clone is selected by conversion and determination with optimization fermentation technological condition and technological condition of segregation and decontamination for products, and the obtained recombinative reducing peptide has bioactivity similar to natural materials.

The invention discloses application of lepidoptera antibiotic peptide Lebocin to pest control. According to the invention, with an expression for inhibiting antibiotic peptide Lebocin, midgut cortex of lepidoptera insects becomes thin, and insect bodies die. However, the reason for thinning of midgut cortex is not the antibacterial action of antibiotic peptide Lebocin, and after insects are fed with different bacteria, the expression of Lebocin in insect midgut does not change obviously while the expression of Lebocinin fat bodies of immune organs is increased obviously, indicating that the high expression of Lebocin in midgut in a metamorphosis period is irrelevant to the antibacterial action of Lebocin, but Lebocin responds to a signal of ecdysone starting development by metamorphosis so as to participate in formation of midgut cortex; Lebocin is related to development and intestinal regeneration. Therefore, according to the invention, an inhibitor with the expression for inhibiting antibiotic peptide Lebocin is applied to preparation of an insecticide for the first time.

The biased residue of an expressible biased peptide library is conveniently altered, without synthesizing a new DNA mixture, by using a DNA encoding said peptide which includes a suppressible stop codon, said codon encoding the biased residue, whereby the amino acid appearing at the biased position may be altered simply by introducing the same DNA mixture into a different suppressor strain.